Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Medtronic
QuintilesIMS
Johnson and Johnson
Julphar
Cerilliant
Colorcon
Baxter
Chubb

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,316,441

« Back to Dashboard

Which drugs does patent 6,316,441 protect, and when does it expire?

Patent 6,316,441 protects SIMBRINZA and is included in one NDA.

This patent has one patent family member in one country.
Summary for Patent: 6,316,441
Title: Brinzolamide and brimonidine for treating glaucoma
Abstract:Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.
Inventor(s): Dean; Thomas R. (Weatherford, TX), Desantis, Jr.; Louis (Fort Worth, TX), York; Billie M. (Conroe, TX)
Assignee: Alcon Manufacturing, Ltd. (Fort Worth, TX)
Application Number:09/832,998
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 6,316,441

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp SIMBRINZA brimonidine tartrate; brinzolamide SUSPENSION/DROPS;OPHTHALMIC 204251-001 Apr 19, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,316,441

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,242,442 Brinzolamide and brimonidine for treating ocular conditions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
Dow
Cipla
QuintilesIMS
Argus Health
Accenture
Deloitte
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.